icon-charity icon-donate-car icon-energy icon-fundraise icon-shop icon-sponsorships

our board

board of directors

John London
Co-founder, Chair
John London co-founded Solving Kids' Cancer in honor of his daughter Penelope, who once told him "I want no one to feel yucky Daddy." He is Board Chair of Solving Kids’ Cancer and serves as a strategic advisor in all areas of therapeutic development. John is a Portfolio Manager at Hudson Bay Capital. He has an MBA from The Wharton School of Business, University of Pennsylvania, and a Bachelor of Arts from Brown University.

Catherine London, JD
Catherine London co-founded Solving Kids' Cancer in honor of her daughter Penelope with her husband John London. An author and writer, Catherine was previously a prosecutor at the New York County District Attorney’s Office. She graduated from New York Law School and has a BA from Brown University. 

Michael Niedzielski
Michael’s daughter, Bianca, was diagnosed with ETMR in 2016, a grade IV brain cancer which she has been fighting ever since. Michael is a Vice President at T Rowe Price and focuses on European small-cap equity. Prior to T Rowe Price, he worked at Fidelity. Michael holds a BA from the University of Chicago and an MBA from Columbia Business School. He is a dual French/Brazilian citizen and currently lives in London with his wife and 2 daughters.

Mark Savoye

Mark N. Savoye is a Vice President and Senior Business Leader, Emerging Payments at MasterCard. He joined MasterCard in 2008; prior to joining MasterCard, Mark served as a Director at American Express. Mark holds a BS degree from New York University Stern School of Business in Marketing and International Business.

Scott Kennedy
Scott Kennedy co-founded Solving Kids’ Cancer as a tribute to his son Hazen, who was diagnosed with neuroblastoma at age 3. As Director of Missions and Programs, Scott is integrally involved in the identification, funding, and management of the organization's scientific programs. He has a BS in Chemistry and Psychology from Indiana University and an MBA from the Asian Institute of Management.

Khalil Barrage
Khalil Barrage is a Managing Director based in New York. He joined Invus in 2003 and set up the Public Equity group, of which he is in charge globally. Prior to joining Invus, Khalil was a portfolio manager with The Olayan Group, New York, in charge of its U.S. equity group. Khalil holds a BA from the American University of Beirut. He is a board member of the Children of Armenia Fund.

Channing Stave, PhD
Channing Stave is Executive Vice President and COO of Disruptyx, a boutique market consulting firm with a unique heuristics-based focus in life sciences, financial services, and retail.  Prior to co-founding Disruptyx, he held leadership positions at IBM, Pfizer, and Express Scripts.  He has a PhD from New York University in Organizational Psychology and a BA from Columbia University.  He is a founding board member of Solving Kids’ Cancer and currently serves as Secretary.  He is also an executive advisor to Baruch’s Zicklin School of Business Consulting Organization.    

scientific advisory board

Hearn Jay Cho, MD, PhD
Mount Sinai Hospital
Assistant Professor of Medicine, Hematology and Medical Oncology

Kenneth J. Cohen, MD, MBA
Johns Hopkins University
Director, Pediatric Neuro-Oncology/Associate Professor of Oncology 

David Kaplan, PhD
Hospital for Sick Children
Co-Chair of Science Advisory Council, Brain Canada

Mark Kieran, MD, PhD
Dana-Farber Cancer Institute
Director of the Pediatric Brain Tumor Program

David Loeb, MD, PhD
Johns Hopkins University
Director of the Musculoskeletal Tumor Program
Associate Professor of Oncology

Chrystal U. Louis, MD, MPH
Baylor College of Medicine
Assistant Professor of Pediatrics

Tobey J. MacDonald, MD
Emory University
Associate Professor Pediatrics Director, Pediatric Neuro-Oncology Program

Rimas J. Orentas, PhD
Lentigen Technology Inc., A Miltenyi Biotec Company‬
Director, Translational Research and Development‪

Stephen S. Roberts, MD
Memorial Sloan-Kettering Cancer Center
Pediatric oncologist

Our impact

Learning that nifurtimox, an anti-
parasitic drug, put a child with neuroblastoma into remission, SKC quickly launched a clinical
trial which has extended the lives of children with this deadly cancer.

Read More

partners wanted

We rely on the support of our
partners to help our thriving
research community. Looking to to create a campaign where the proceeds go directly to funding a trial that you believe in?

Read More
we proactively drive the creation of innovative treatments to help kids that are sick right now. by using small, nimble trials, we discover new treatment options at revolutionary rates. See How